Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pharmaceutical giant Pfizer Inc. PFE has signed a significant licensing agreement with China's 3SBio Inc. for an experimental cancer drug, SSGJ-707. According to the deal, Pfizer will pay $1.25 ...

Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE ...

Pfizer Inc. (PFE) Inks $6 Billion Cancer Drug Licensing Agreement with China’s 3SBio According to Pfizer Inc. (NYSE:PFE), the drug candidate is being tested for use against non-small cell lung cancer, ...

Additional milestone payments could reach up to $4.8 billion, alongside tiered double-digit royalties on future sales if the drug receives approval ... planning details or potential impacts on ...

The agreement covers the development, manufacturing and commercialisation of the drug. Pfizer has been granted a global license, excluding China, as well as the option to obtain commercialisation ...

3SBio’s share price [HKG:1530] surged 32.5 percent to ... plus tiered double-digit royalties on sales if the drug receives regulatory approval. 3SBio's tie-up with Pfizer has exceeded expectations in ...

Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China ... Citigroup raised 3SBio’s price target to HK$21.00 ($2.7) from HK$13.00 after the deal.